MARKET

CBPO

CBPO

China Biologic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

110.12
+2.00
+1.85%
After Hours: 110.12 0 0.00% 16:00 05/28 EDT
OPEN
107.14
PREV CLOSE
108.12
HIGH
110.49
LOW
107.03
VOLUME
71.30K
TURNOVER
--
52 WEEK HIGH
119.44
52 WEEK LOW
88.00
MARKET CAP
4.24B
P/E (TTM)
27.89
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CBPO stock price target is 96.22 with a high estimate of 115.00 and a low estimate of 74.00.

EPS

CBPO News

More
China Biologic Products Inc (CBPO) Q1 2020 Earnings Call Transcript
Motley Fool · 05/21 21:00
China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/21 15:39
China Biologic Comments on the Xinjiang Deyuan and Shuanglin Transaction
PR Newswire · 05/20 21:45
China Biologic Products Reports Xinjiang Deyuan Bioengineering Materially Breached Strategic Cooperation With Co. By Entering Plasma Supply Deals With Southern Shuanglin Bio-Pharmacy, Co. Will Take All Necessary Measures To Protect Its Rights
Benzinga · 05/20 20:48
China Biologic Products Q1 EPS $1.560 Beats $1.380 Estimate, Sales $162.600M Up From $129.784M YoY
China Biologic Products (NASDAQ:CBPO) reported quarterly earnings of $1.560 per share which beat the analyst consensus estimate of $1.380 by 13.04 percent. This is a 40.54 percent increase over earnings of $1.110 per
Benzinga · 05/20 20:32
China Biologic Reports Financial Results for the First Quarter of 2020
China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the first quarter of 2020.
PR Newswire · 05/20 20:30
The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows
Biotech stocks had another up week, with the American Society of Gene & Stem Cell Therapy virtual conference presentations and the ASCO abstracts made available online Thursday calling the shots. Earnings news flow continued to taper.
Benzinga · 05/17 16:30
China Biologic Products to Report First Quarter 2020 Financial Results
PR Newswire · 05/12 13:30

Industry

Biotechnology & Medical Research
+0.35%
Pharmaceuticals & Medical Research
+1.04%

Hot Stocks

Symbol
Price
%Change

About CBPO

China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company's products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).
More

Webull offers kinds of China Biologic Products Holdings Inc stock information, including NASDAQ:CBPO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBPO stock news, and many more online research tools to help you make informed decisions.